Dr. Christina Chang is the Director of the Division of Urology, Obstetrics and Gynecology (DUOG) in the Office of New Drugs in the Center for Drug Evaluation and Research at U.S. FDA. In this capacity, she oversees a diverse group of drugs and therapeutic biologics for the management of benign urologic, obstetric, and gynecologic conditions. She has led the facilitation and assessment of many development programs in these areas, including products to manage endometriosis-associated pain, heavy menstrual bleeding due to uterine fibroids, products to treat pre-malignant dysplasia of the cervix, and products to prevent preterm birth. Dr. Chang has co-authored several publications on regulatory science and complex FDA decisions. She started her FDA career in 2007 as a clinical reviewer in the Division of Nonprescription Clinical Evaluation and took on the role of clinical team leader in DUOG in 2013. Dr. Chang is a board-certified obstetrician/gynecologist. She obtained her bachelor’s degree in Biochemistry from University of California at Berkeley and her medical degree from University of Chicago Pritzker School of Medicine. She also received her Master of Public Health with Honors from the Johns Hopkins University School of Hygiene and Public Health. She completed her obstetrics and gynecology residency at Washington Hospital Center in Washington D.C. Prior to joining the FDA, she provided full-scope obstetric and gynecologic care to adolescent and adult females for seven years and founded her own practice.